Elevance Health, Inc. (NYSE:ELV) Receives $390.55 Average Target Price from Analysts

Elevance Health, Inc. (NYSE:ELV) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-two research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $390.55.

A number of equities research analysts have recently issued reports on ELV shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $332.00 target price on shares of Elevance Health in a research note on Thursday, January 29th. UBS Group set a $400.00 price objective on Elevance Health in a research note on Thursday, January 29th. Morgan Stanley reduced their target price on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 17th. JPMorgan Chase & Co. boosted their price target on Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Finally, Wolfe Research set a $425.00 price objective on Elevance Health and gave the stock an “outperform” rating in a research note on Thursday, January 8th.

Institutional Investors Weigh In On Elevance Health

Several institutional investors and hedge funds have recently bought and sold shares of ELV. Tempo Wealth LLC acquired a new stake in shares of Elevance Health during the 4th quarter worth approximately $391,000. MidFirst Bank bought a new position in Elevance Health during the 4th quarter worth $2,947,000. DGS Capital Management LLC grew its stake in Elevance Health by 5.1% during the 4th quarter. DGS Capital Management LLC now owns 3,086 shares of the company’s stock worth $1,082,000 after buying an additional 151 shares during the last quarter. Lynch Investment Planning LLC acquired a new stake in Elevance Health in the fourth quarter worth $264,000. Finally, Monetary Solutions Ltd bought a new stake in Elevance Health in the fourth quarter valued at $53,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Price Performance

Shares of NYSE ELV opened at $330.52 on Monday. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. Elevance Health has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The business has a 50 day moving average price of $351.06 and a two-hundred day moving average price of $335.28. The firm has a market cap of $72.95 billion, a PE ratio of 13.16, a price-to-earnings-growth ratio of 1.81 and a beta of 0.50.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business’s revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the business posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Sell-side analysts expect that Elevance Health will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Tuesday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is 27.23%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.